Caris Life Sciences, Inc. is 2.0x more valuable than GRAIL, LLC by market capitalization ($5.09 B vs $2.58 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GRAL | CAI |
|---|---|---|
| Market cap | $2.58 B | $5.09 B |
| US-listed rank | #1936 | #1390 |
| Revenue (latest FY) | $147.17M | $812.03M |
| Net income (latest FY) | -$408.35M | -$68.09M |
| Net margin | -277.5% | -8.4% |
| SEC filings | 228 | 102 |
Caris Life Sciences, Inc. is 2.0x more valuable than GRAIL, LLC by market capitalization ($5.09 B vs $2.58 B).
In their latest fiscal years, GRAIL, LLC reported $147.17M in revenue while Caris Life Sciences, Inc. reported $812.03M.
Full pages: GRAIL, LLC and Caris Life Sciences, Inc., or browse the full rankings.